AAP
DNLI icon

Arax Advisory Partners’s Denali Therapeutics DNLI Stock Holding History

Arax Advisory Partners’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$42.7K Buy
1,661
+1,360
+452% +$27.9K ﹤0.01% 3403
2026
Q1 		$5.8K Buy
301
+103
+52% +$2.05K ﹤0.01% 2715
2025
Q4 		$3.27K Buy
+198
New +$3.34K ﹤0.01% 3064
2025
Q3 		– Sell
-52
Closed -$728 – 3760
2025
Q2 		$728 Buy
+52
New +$732 ﹤0.01% 2869
2025
Q1 		– Sell
-117
Closed -$2.38K – 2770
2024
Q4 		$2.38K Hold
117
– – ﹤0.01% 1968
2024
Q3 		$3.41K Hold
117
– – ﹤0.01% 1872
2024
Q2 		$2.72K Buy
+117
New +$2.25K ﹤0.01% 1852

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Arax Advisory Partners's DNLI Position: Q2 2026 in Review

Arax Advisory Partners increased its Denali Therapeutics (DNLI) stake by 452% in Q2 2026, buying an estimated $27.9K and bringing the position to 1,661 shares worth $42.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3403.

Arax Advisory Partners first reported a position in DNLI in Q2 2024 and has held it in 7 quarters since. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Arax Advisory Partners held 1,661 shares of Denali Therapeutics worth $42.7K as of Q2 2026.
  • Arax Advisory Partners bought 1,360 Denali Therapeutics shares in Q2 2026, an estimated $27.9K.
  • Denali Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #3403 holding.
  • Arax Advisory Partners first reported a position in Denali Therapeutics in Q2 2024 and has held it in 7 quarters since.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.